PT1993589E - Tratamentos para doenças neurológicas - Google Patents

Tratamentos para doenças neurológicas

Info

Publication number
PT1993589E
PT1993589E PT77520898T PT07752089T PT1993589E PT 1993589 E PT1993589 E PT 1993589E PT 77520898 T PT77520898 T PT 77520898T PT 07752089 T PT07752089 T PT 07752089T PT 1993589 E PT1993589 E PT 1993589E
Authority
PT
Portugal
Prior art keywords
treatments
neurological disorders
treating
injuries
improving
Prior art date
Application number
PT77520898T
Other languages
English (en)
Inventor
Anthony Rossomando
Dinah Wen-Yee Sah
Frank Porreca
Original Assignee
Biogen Idec Inc
Univ Arizona State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Univ Arizona State filed Critical Biogen Idec Inc
Publication of PT1993589E publication Critical patent/PT1993589E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PT77520898T 2006-02-27 2007-02-27 Tratamentos para doenças neurológicas PT1993589E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77749306P 2006-02-27 2006-02-27
US86385206P 2006-11-01 2006-11-01

Publications (1)

Publication Number Publication Date
PT1993589E true PT1993589E (pt) 2013-12-23

Family

ID=38459674

Family Applications (1)

Application Number Title Priority Date Filing Date
PT77520898T PT1993589E (pt) 2006-02-27 2007-02-27 Tratamentos para doenças neurológicas

Country Status (10)

Country Link
US (1) US10328125B2 (pt)
EP (2) EP2609930A3 (pt)
DK (1) DK1993589T3 (pt)
ES (1) ES2439740T3 (pt)
HR (1) HRP20131188T1 (pt)
PL (1) PL1993589T3 (pt)
PT (1) PT1993589E (pt)
RS (1) RS53089B (pt)
TW (1) TWI501774B (pt)
WO (1) WO2007100898A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
ES2479942T3 (es) 2003-04-18 2014-07-25 Biogen Idec Ma Inc. Neublastina glucosilada conjugada con polímero
RS51453B (en) * 2004-08-19 2011-04-30 Biogen Idec Ma Inc. NEUBLASTIN
AU2005277227B2 (en) 2004-08-19 2011-10-06 Biogen Ma Inc. Refolding transforming growth factor beta family proteins
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
WO2007103182A2 (en) * 2006-03-01 2007-09-13 Biogen Idec Ma Inc. Compostions and methods for administering gdnf ligand family proteins
JP5583005B2 (ja) 2007-05-01 2014-09-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管新生を増大させるための組成物および方法
EP2205634A2 (en) * 2007-08-08 2010-07-14 Biogen Idec MA, Inc. Anti-neublastin antibodies and uses thereof
ES2584068T3 (es) 2010-10-01 2016-09-23 Nsgene A/S Uso de meteorina para el tratamiento de alodinia, hiperalgesia, dolor espontáneo y dolor fantasma
KR102075881B1 (ko) 2011-09-05 2020-02-11 호바 세라퓨틱스 에이피에스 이질통, 통각과민증, 자발통 및 환상통의 치료
US20210312824A1 (en) * 2020-04-01 2021-10-07 Magicom Inc. Smart pen apparatus
JP2024518433A (ja) 2021-05-06 2024-05-01 ホバ セラピューティクス エーピーエス 化学療法誘発性神経障害性疼痛の予防及び治療
CA3239550A1 (en) 2021-12-10 2023-06-15 Kenneth Petersen Treatment of nociceptive pain

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4407957A (en) * 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
US5525464A (en) * 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5084350A (en) * 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
DE69221484T2 (de) 1991-04-25 1998-02-19 Univ Brown Res Found Implantierbare, biokompatible immunisolator-trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
JP3230056B2 (ja) 1991-07-02 2001-11-19 インヘイル・インコーポレーテッド 薬剤のエーロゾル化服用量を形成する装置
GEP20002243B (en) 1991-09-20 2000-09-25 Amgen Inc Glial Derived Neurotrophic Factor
US5939524A (en) 1991-12-09 1999-08-17 The Scripps Research Institute Platelet GPIII P1A1 and P1A2 epitopes, their preparation and use
US5414135A (en) * 1991-12-30 1995-05-09 Sterling Winthrop Inc. Vinyl sulfone coupling of polyoxyalkylenes to proteins
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
EP0679088B1 (en) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
US5349056A (en) 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
CA2092271C (en) * 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
DE69430824T2 (de) 1993-08-12 2003-01-23 Neurotech S.A., Evry Biokompatible immunoisolatorische Kapseln, die genetisch veränderte Zellen enthalten
DE4339605A1 (de) 1993-11-20 1995-05-24 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden
US5834029A (en) 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
WO2001053486A1 (en) 1999-03-08 2001-07-26 Genentech, Inc. Compositions and methods for the treatment of tumor
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US5770577A (en) 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5733729A (en) 1995-09-14 1998-03-31 Affymetrix, Inc. Computer-aided probability base calling for arrays of nucleic acid probes on chips
US6184200B1 (en) 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US6063757A (en) 1995-11-29 2000-05-16 Urso; Richard G. Wound treatment method with nerve growth factor
WO1997019693A1 (en) 1995-11-29 1997-06-05 Amgen Inc. Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product
DE69636739T2 (de) * 1995-12-21 2007-10-18 Ajinomoto Co., Inc. Verfahren zur rückfaltung von menschlichem activin a
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
US5754524A (en) 1996-08-30 1998-05-19 Wark; Barry J. Computerized method and system for analysis of an electrophoresis gel test
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
JP2001501093A (ja) * 1996-09-26 2001-01-30 メディカル リサーチ カウンシル シャペロン断片
KR100195886B1 (ko) 1996-11-01 1999-06-15 김상조 당뇨병 치료용 의약조성물
EP0961830A1 (en) 1997-01-29 1999-12-08 Neurosearch A/S EXPRESSION VECTORS AND METHODS FOR $i(IN VIVO) EXPRESSION OF THERAPEUTIC POLYPEPTIDES
CN1269805A (zh) 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
GB9718908D0 (en) 1997-09-05 1997-11-12 Rowett Research Services Limit Proteins
WO1999049039A2 (en) 1998-03-23 1999-09-30 Genentech, Inc. GFRα3 AND ITS USES
US6653098B1 (en) 1998-02-23 2003-11-25 G. D. Searle & Co. Method of producing mouse and human endostatin
US20020055467A1 (en) 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US7067473B1 (en) 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
SK287361B6 (sk) 1998-07-14 2010-08-09 Janssen Pharmaceutica N. V. Ľudský neurotrofický rastový faktor a jeho použitie
AU771239C (en) 1998-09-14 2004-10-14 Soren Buus A method of producing a functional immunoglobulin superfamily protein
AU778998B2 (en) 1998-09-22 2004-12-23 University Of Maryland At Baltimore Cystine knot growth factor mutants
US6284540B1 (en) 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
EP1137774A2 (en) 1998-12-09 2001-10-04 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
US6361771B1 (en) 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
JP2003525916A (ja) * 1999-04-22 2003-09-02 エイドゲントシッシュ テクニーシェ ホッシュール チューリッヒ モディファイドタンパク質マトリクス
ES2287020T3 (es) 1999-06-02 2007-12-16 Genentech, Inc. Procedimiento y composiciones para inhibir el crecimiento de celulas neoplasicas.
PT1223966E (pt) * 1999-10-29 2003-09-30 Biopharm Ges Biotechn Entwickl Utilizacao do gdnf para tratamento de defeitos na cornea
US6866851B1 (en) 1999-12-28 2005-03-15 Washington University GFRα1-RET specific agonists and methods therefor
AU2001289307A1 (en) 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
EP1284987B1 (en) 2000-05-16 2007-07-18 Bolder Biotechnology, Inc. Methods for refolding proteins containing free cysteine residues
CA2327208A1 (en) * 2000-11-30 2002-05-30 The Government Of The United States Of America Methods of increasing distribution of therapeutic agents
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
KR20040067841A (ko) * 2000-12-22 2004-07-30 제넨테크, 인크. Ｇｄｎｆ 리간드 족의 구성원인 아르테민의 신규 용도
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
WO2002060929A2 (en) 2001-02-01 2002-08-08 Biogen, Inc. Polymer conjugates of neublastin and methods of using same
US6969360B1 (en) 2001-02-13 2005-11-29 Northwestern University Spinal proprioception methods and related systems
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US20040077543A1 (en) 2001-03-28 2004-04-22 Sah Dinah W. Y. Treatment using neublastin polypeptides
EP1395279B1 (en) 2001-03-28 2011-10-05 Biogen Idec MA Inc. Use of neublastin polypeptides for treating neuropathic pain
JP2004527573A (ja) * 2001-04-24 2004-09-09 パーデュー・リサーチ・ファウンデーション 哺乳類の神経組織損傷の治療のための方法及び組成物
US7250495B2 (en) * 2001-06-20 2007-07-31 Genentech, Inc. PRO20044 polypeptides
US20040028613A1 (en) * 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
US7827106B2 (en) * 2001-07-10 2010-11-02 American Express Travel Related Services Company, Inc. System and method for manufacturing a punch-out RFID transaction device
US7129085B2 (en) * 2001-10-11 2006-10-31 Bristol-Myers Squibb Company Polynucleotides encoding a human leucine-rich repeat domain containing protein, HLLRCR-1
EP1314739A1 (en) 2001-11-22 2003-05-28 Bayer Ag Process for renaturation of recombinant, disulfide containing proteins at high protein concentrations in the presence of amines
GB0205022D0 (en) * 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
JP4310608B2 (ja) 2002-04-25 2009-08-12 東洋紡績株式会社 Ｈｓｐ７０ファミリータンパク質基質結合ドメインフラグメントの利用方法
DE10229175A1 (de) 2002-06-28 2004-01-15 Valeo Klimasysteme Gmbh Zylinderklappe mit strukturierter rauher Oberfläche
ES2479942T3 (es) 2003-04-18 2014-07-25 Biogen Idec Ma Inc. Neublastina glucosilada conjugada con polímero
ATE423134T1 (de) 2003-06-10 2009-03-15 Nsgene As Verbesserte sezernierung von neublastin
US7598059B2 (en) * 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
JP2007509109A (ja) 2003-10-20 2007-04-12 エヌエスジーン・アクティーゼルスカブ パーキンソン病のインビボ遺伝子治療
US20050180957A1 (en) * 2004-01-16 2005-08-18 Scharp David W. Method of using fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells
US20060014288A1 (en) 2004-06-23 2006-01-19 Tissuegene, Inc. Nerve regeneration
US7598356B2 (en) * 2004-07-08 2009-10-06 Board of Regents of the University of Nebraska by and on behalf of the University of Nebraska Medical Center Method for purifying a protein of the cystine-knot superfamily
RS51453B (en) 2004-08-19 2011-04-30 Biogen Idec Ma Inc. NEUBLASTIN
AU2005277227B2 (en) 2004-08-19 2011-10-06 Biogen Ma Inc. Refolding transforming growth factor beta family proteins
US20080260702A1 (en) 2005-10-11 2008-10-23 Jesper Roland Jorgensen Treatment of Retinopathies Using Gfra3 Agonists
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
WO2007103182A2 (en) 2006-03-01 2007-09-13 Biogen Idec Ma Inc. Compostions and methods for administering gdnf ligand family proteins
ES2618787T5 (es) * 2006-04-25 2022-10-21 Univ California Administración de factores de crecimiento para el tratamiento de trastornos del SNC
JP5583005B2 (ja) * 2007-05-01 2014-09-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管新生を増大させるための組成物および方法
EP2205634A2 (en) 2007-08-08 2010-07-14 Biogen Idec MA, Inc. Anti-neublastin antibodies and uses thereof

Also Published As

Publication number Publication date
US10328125B2 (en) 2019-06-25
EP1993589A4 (en) 2010-07-21
HRP20131188T1 (hr) 2014-01-17
EP2609930A2 (en) 2013-07-03
WO2007100898A3 (en) 2008-01-17
PL1993589T3 (pl) 2014-03-31
EP1993589B1 (en) 2013-09-25
ES2439740T3 (es) 2014-01-24
DK1993589T3 (da) 2014-01-06
EP1993589A2 (en) 2008-11-26
TW200744629A (en) 2007-12-16
TWI501774B (zh) 2015-10-01
RS53089B (en) 2014-06-30
WO2007100898A2 (en) 2007-09-07
EP2609930A3 (en) 2013-07-17
US20090221495A1 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
PT1993589E (pt) Tratamentos para doenças neurológicas
JP2020192343A5 (pt)
BRPI0415558A (pt) tratamentos com toxina de botulina de distúrbios neurológicos e neuropsiquiátricos
WO2004022156A3 (en) Methods for treating central nervous system damage
EP2286840A3 (en) Treatment of obesity and related diseases
DE602006016572D1 (de) Neurostimulationsstellen-screening
WO2004060146A3 (en) Method of treatment for central nervous system injury
WO2008033792A3 (en) Repetitive transcranial magnetic stimulation for movement disorders
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
SI1913947T1 (sl) Kombinirana terapija za zdravljenje raka
ATE441419T1 (de) Verwendung von loteprednoletabonat zur behanldung von trockenen augen
ATE544463T1 (de) Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen
IS8540A (is) Notkun TWEAK stilla og tálma til að meðhöndla taugasjúkdóma
WO2005081619A3 (en) Compounds and methods for increasing neurogenesis
PL1631234T3 (pl) Kompozycje i sposoby leczenia uszkodzeń OUN
WO2010018996A3 (ko) 인간 신경줄기세포 및 이를 이용한 중추 또는 말초 신경계 질환 및 손상 치료용 약학적 조성물
DE602006002135D1 (de) Verwendung von Naloxon zur Behandlung von Essstörungen
Park et al. Repetitive transcranial magnetic stimulation to treat depression and insomnia with chronic low back pain
CN201710815U (zh) 一种用于刺激耳迷走神经的头戴式耳部电极
IL178490A0 (en) Treatment of diseases
EP1297849A4 (en) CURATIVE AGENT FOR OPTICAL AND SIMILAR NERVE DISEASES
ATE394122T1 (de) Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen
CY1114723T1 (el) Θεραπειες για νευρολογικες διαταραχες
WO2007117440A3 (en) Stimulation of neuron regeneration by secretory leukocyte protease inhibitor
KR102716573B1 (ko) 작업치료기